Open-label, Multli-center, Phase 1b/2a Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Patients With Macular Edema

Trial Profile

Open-label, Multli-center, Phase 1b/2a Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Patients With Macular Edema

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 05 Aug 2016

At a glance

  • Drugs Dexamethasone (Primary)
  • Indications Retinal oedema
  • Focus Proof of concept; Therapeutic Use
  • Sponsors EyeGate Pharma
  • Most Recent Events

    • 24 Jun 2016 Status changed from recruiting to discontinued.
    • 13 May 2016 Top-line data from this trial are expected in the second quarter of 2016, according to an Eyegate Pharmaceuticals media release.
    • 19 Jan 2016 Planned End Date changed from 1 Mar 2016 to 1 Aug 2016 ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top